COVID-19: Innovating the research and therapeutic response
In Oregon, scores of research labs temporarily halted work. Myriad local scientists and researchers quickly pivoted to focus on therapeutic development, create diagnostic assays and marshal high intellect, innovating curative and preventive strategies to address the novel coronavirus.
Tune in on April 30 to Bio, Business and Good Beans: Zoom Coffee Break to hear researchers Bernard Fox, Ph.D., co-founder and CEO of UbiVac and the Chief of Molecular and Tumor Immunology at Providence Cancer Institute, and Peter Barr-Gillespie, Ph.D., Chief Research Officer and Executive Vice President at Oregon Health & Science University. Drs. Fox and Barr-Gillespie will present the emerging horizons of novel coronavirus research including, characterizing the anti-viral immune response in humans and mice, vaccine manufacturing, sero surveillance of patient-facing health workers and validation methods to decontaminate workers’ PPE. Listen to understand how the research designed to combat COVID-19 is starting here. Both Drs. Fox and Barr-Gillespie are board members of Oregon Bio.
WHEN: Thursday, April 30; 9:30 – 10 a.m.
WHERE: Pre-register at https://zoom.us/webinar/register/WN_q1Lul91fQgeSIgECmZJ7OQ and look for the invitation email
Oregon Bio offers a 30-minute fast-track, Q&A session on key topics to help academic institutions, labs and R&D companies, bio businesses, suppliers/vendors and organizations. In this time of COVID-19, info is rapidly changing and so is the speed of business. We want to help you keep updated the topics of the day and how you and your colleagues can benefit. These are content-driven, free sessions available in real time in Zoom video and audio (or audio only).